What "Preparation" Means in Clinical Settings

What this page is

In psychedelic research and licensed services, "preparation" means meetings with trained staff before any drug session. This page describes what published protocols and regulators say. It is not a guide to preparing for any substance, and it gives no amounts or steps for use.

Evidence label used here: insufficient evidence (too little research to judge). Researcher guidelines are described as guidelines, not as tested results.

What preparation covers in trials

• Time and staffing. In a phase 3 MDMA trial for PTSD, participants had three 90-minute preparation sessions with a two-person therapy team that included at least one licensed therapist. [1]
• Part of a larger therapy block. In a psilocybin trial for major depression, supportive psychotherapy totaled about 11 hours across the course. [2]
• Safety rationale. Published safety guidelines for hallucinogen research list careful volunteer preparation and building trust and rapport between monitors and the volunteer before the session among the safeguards. [3] These are guidelines from researchers. They are not proof that preparation, on its own, prevents harm.

What preparation covers in Oregon's licensed program

Oregon Health Authority describes (read 2026-10-22) a preparation session that includes client intake and review of informed consent, the client bill of rights, accessibility needs, safety and support planning, and transportation planning. [4] Each client completes a Safety and Support Plan with the facilitator, and an individual transportation plan before the administration session. [4]

Preparation is also where eligibility is checked. In Oregon the person decides whether to go ahead, and the facilitator decides whether they can provide services. [4] See screening and eligibility and informed consent.

How training programs treat it

Colorado's state-approved facilitator training programs must include at least 150 hours of coursework, with Screening at 5 hours and Preparation at 10 hours among the listed topics. [5] That shows regulators regard preparation as a distinct skill. It does not show how well it works.

What the evidence says

• Does preparation improve outcomes? Label: insufficient evidence. The FDA states that the contribution of the psychotherapy component to any observed efficacy has not been characterized. [6] Proper evidence not found for a trial that tested preparation separately from the rest of the course; we checked the regulator guidance, the two trials above, and a systematic review of psychological interventions in psychedelic research, which found ad hoc and adapted methods rather than a standard one. [7]
• Expectations. Strong expectations can influence results. The FDA suggests trials assess participants' expectations about drug effects before randomization and at the end of treatment. [6] A review also flags the potential suggestive effects of the information given to patients. [7] Preparation can therefore shape results as well as safety, which is a reason to read trial results with care. See context and expectancy.

What preparation is not

• It is not medical clearance. Only a clinician who knows your history can judge your risks.
• It is not a reason to attempt a similar experience outside a monitored setting. The safeguards described above are tied to settings with trained staff and medical backup.
• It does not remove risk. Trials report adverse events despite preparation. See adverse effects and contraindications.

Related guides

• What is psychedelic-assisted therapy?
• What integration means
• Clinical monitoring during sessions